Monday, October 22, 2018
News

Cipla gets USFDAs final approval for generic Isuprel

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

Mumbai | Thursday, Jun 14 2018 IST
Cipla, announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Isoproterenol Hydrochloride Injection USP, 0.2mg/mL, single-usesterile Ampoule from the United States Food and Drug Administration (US FDA).

Cipla's Isoproterenol Hydrochloride Injection USP, 0.2mg/mL, ampoule is APrated generic therapeutic equivalent version of Hospira Inc's Isuprel Injection, 0.2mg/ml, Cipla said in a filing with BSE.

Isoproterenol Hydrochloride are indicated for the treatment of Mild or transient episodes of heart block that do not require electric shock or pacemaker therapy.

It is also used As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock.

According to IQVIA (IMS Health), Isuprel Injection and its generic equivalents had US sales of approximately USD 148M for the 12-month period ending April 2018, the filing added.

UNI JS AE 1455

-- (UNI) -- C-1-DL0169-1402440.Xml

 
  LATEST COMMENTS (0)
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Vice President to inaugurate SAGAR Disco...
Congress takes aim again at Modi, Jaitle...
Train service suspended for security re...
Ganga Fast: Sant Gopal Das critical on 1...
UP Legislative council chairman's wife a...
BJP to fine tune strategies for three ma...
More...    
 
 Top Stories
IL&FS Group appoints FTAs to harmon... 
Liquidity concerns, weak rupee dent... 
US Embassy launches mentorship prog... 
India, Myanmar review ties, sign po... 
Bangladesh observes road safety day... 
NHRC issues notice to DGP Chhattisg... 
Real Madrid holds practice session ... 
68% rise in crorepatis since 2014, ...